Here’s What the Wall Street Thinks About Revolution Medicines (RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 6, Revolution Medicines, Inc. (NASDAQ:RVMD) released its financial and business update for the fiscal second quarter of 2025. The company reported advancement in its key drug Daraxonrasib, which is currently in Phase 3 trials for patients with pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Wall Street is optimistic regarding this clinical-stage company, with analysts’ average 12-month price target of $72 representing 101.23% upside from the current level.

Here's What the Wall Street Thinks About Revolution Medicines (RVMD)

Recently, on August 15, Wells Fargo initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with a Buy rating and a $67 price target. The firm noted that the company has worked on a de-risked profile for this drug, meaning that it has a lower chance of failure. The firm expects a positive result from the Phase 3 trial, which is due in 2026.

Revolution Medicines, Inc. (NASDAQ:RVMD) develops targeted cancer therapies for RAS-addicted cancers. They create drugs called RAS(ON) inhibitors that directly target specific RAS mutations.

While we acknowledge the potential of RVMD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RVMD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.